ReviewNPJ breast cancer2020
Clinical utility of genomic signatures in young breast cancer patients: a systematic review.
Review in NPJ breast cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.Journal of the National Cancer Institute · 2022Trial
- Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.Nature reviews. Clinical oncology · 2026Review
- Dose-dense adjuvant chemotherapy for high-risk early breast cancer: its role in the era of personalised oncology.Gland surgery · 2025Article
- Unveiling the Stroma: Reproductive Factors and the Tumor Microenvironment in African Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey.Therapeutic advances in medical oncology · 2025Article
- Disparities in the Occurrence of Long-Term Effects of Bone Marrow Suppression after Treatment in Adolescent Young Adult Breast Cancer Survivors.Annals of surgical oncology · 2024Article
- Ovarian Suppression: Early Menopause and Late Effects.Current treatment options in oncology · 2024Review
- Young Women with Breast Cancer: The Current Role of Precision Oncology.Journal of personalized medicine · 2023Review
- Breast cancer in young Indian women: factors, challenges in screening, and upcoming diagnostics.Journal of cancer research and clinical oncology · 2023Review
- Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization.European journal of breast health · 2023Article
- Survival analysis of breast cancer patients after diagnosis of second primary malignancies, focusing on the second primary hematologic malignancy.Annals of surgical treatment and research · 2023Article
- Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Article
- Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.NPJ breast cancer · 2023Article
- PROCURE European consensus on breast cancer multigene signatures in early breast cancer management.NPJ breast cancer · 2023Article
- Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.Frontiers in oncology · 2023Article
- A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.British journal of cancer · 2022Article
- Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.The oncologist · 2022Observational
- Article
- Editorial: Breast Cancer in Young Women: Dedicated Research Efforts Are Needed.Frontiers in oncology · 2022Article
- Transcriptomic profiling of Indian breast cancer patients revealed subtype-specific mRNA and lncRNA signatures.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk stratification by genomic signatures has been shown to improve prognostication and guide treatment decisions among patients with hormone-sensitive breast cancer. However, their role in young women has not been fully elucidated. In this review, a systematic search was conducted for published articles and abstracts from major congresses that evaluated the use of genomic signatures in young breast cancer patients. A total of 71 studies were analyzed, including 561,188 patients of whom 27,748 (4.9%) were young. Women aged ≤40 years were subjected to genomic testing at a similar rate to older women but had a higher proportion of intermediate- to high-risk tumors when classified by EndoPredict (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.